Abstract

To investigate the relate of miR-34a/b/c expression with clinical features and prognosis in elderly patients with acute myeloid leukemia (AML). 91 elderly patients with AML who consecutively underwent chemotherapy were enrolled in AML group, and 21 patients with non-hematologic malignancies were consider as controls. MiR-34a/b/c expression in bone marrow mononuclear cells (BMMNC) were detected by quantitative polymerase chain reaction (qPCR). All elderly AML patients received the routine induction chemotherapy based on their disease state and risk stratification. The treatment response was assessed. Overall survival (OS) time and event-free survival (EFS) time were recorded. The median miR-34a and miR-34b (all P<0.01) levels in the elderly AML group were lower than those in the control group, while miR-34c level was not different between two groups (P>0.05). MiR-34a high expression correlated with non FLT3-ITD mutation (P<0.05) and lower-risk stage (P<0.05) in elderly AML patients, miR-34b high expression correlated with normal karyotype (NK) (P<0.05), CEBPA double mutation (P<0.01), NPM1 mutation (P<0.05), and WBC count≤10×109/L (P<0.05), while miR-34c expression did not correlate with clinical features of patients (all P>0.05). In addition, the miR-34a high expression correlated with a high CR rate (P<0.05), long EFS (P<0.01) time and OS time (P<0.01) in elderly AML patients, while miR-34b/c expressions not correlated with CR rate, EFS and OS time in patients (all P>0.05). The miR-34a/b are low expressed in elderly AML patients, which associates with good clinical manifisfation of patients, and the miR-34a high expression can predict a good prognosis of elderly AML patients to some extent.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call